Tirzepatide Reconstitution Guide
Part of the full Tirzepatide guide - a unimolecular dual gip and glp-1 receptor agonist reference compound, identity-verified with a COA on every vial.
In brief
Reconstitution of lyophilized tirzepatide for in-vitro research is a laboratory-handling procedure, not a dosing protocol. The objective is to convert the supplied freeze-dried 39-residue acylated peptide (molecular weight 4813.5 g/mol, formula C225H348N48O68) into a defined-concentration stock suitable for the recombinant-cell cAMP potency assays that characterize this dual GIPR/GLP-1R agonist. Because the reported activities are sub-nanomolar (GIPR EC50 ~ 0.042 nM, GLP-1R EC50 ~ 0.086 nM), the practical aim is a documented, traceable molar stock that can be serially diluted into the picomolar-to-nanomolar working range without introducing concentration error. The molecular weight 4813.5 g/mol is the single most important constant in this procedure: it is the conversion factor between the mass of peptide supplied and the molar concentration the assay actually requires. The steps and storage notes below describe bench preparation only.
The detail
A closer look
01
Diluent choice and concentration math
Bacteriostatic water is the conventional reconstitution diluent for lyophilized research peptides because the benzyl-alcohol preservative limits microbial growth in a multi-aliquot stock. The concentration calculation is mass-over-volume converted to molarity through the 4813.5 g/mol molecular weight: dividing the labeled peptide mass by the volume of bacteriostatic water added gives a mass-per-volume concentration, which is then divided by 4813.5 g/mol to express the stock in molar units. Working assay concentrations in the reported nanomolar and sub-nanomolar range are then reached by serial dilution from that documented stock into culture medium or assay buffer. Note that the acylated peptide's reversible albumin binding means dilution into serum- or albumin-containing media can reduce free-peptide availability, a factor worth accounting for when setting target free concentrations.
02
Storage and stability handling
Following general peptide-handling practice, the reconstituted stock is aliquoted into single-use volumes to avoid repeated freeze-thaw, labeled with concentration and date, and stored cold for traceability. Lyophilized material is the most stable form and is kept cold and dry until use; once in solution, the peptide is more labile and benefits from minimized handling. Aliquoting at the point of reconstitution is the key discipline - it converts a single stock into many single-use portions so no aliquot endures more than one freeze-thaw cycle. These are general lyophilized-peptide storage principles; the entry provides no tirzepatide-specific stability constants, so storage choices should follow conservative peptide-class defaults rather than assumed peptide-specific limits.
Step by step
How Tirzepatide is reconstituted
A bench reference for handling and preparation in an in-vitro research setting. Not a personal dosing protocol.
- 1
Equilibrate the sealed lyophilized tirzepatide vial and the bacteriostatic water diluent to room temperature before opening, to limit condensation on the cold peptide.
- 2
Calculate the target stock concentration from the labeled peptide mass and the diluent volume to be added; use the molecular weight 4813.5 g/mol to convert the resulting mass-per-volume concentration to molarity.
- 3
Sanitize the vial septa and draw the predetermined volume of bacteriostatic water with a clean syringe or pipette.
- 4
Add the diluent slowly down the inner wall of the vial onto the lyophilized cake rather than directly onto it, to reduce shear on the acylated peptide.
- 5
Allow the peptide to dissolve undisturbed, then swirl gently (do not vortex or shake vigorously) until the solution is clear, indicating full reconstitution.
- 6
Verify and record the exact mass and final volume so the molar concentration of the stock is documented and traceable against the 4813.5 g/mol constant.
- 7
Prepare assay working concentrations within the reported sub-nanomolar-to-nanomolar in-vitro range by serial dilution into culture medium or assay buffer, accounting for albumin binding in serum-containing media.
- 8
Aliquot the stock into single-use volumes to avoid repeated freeze-thaw, label each with concentration and date, and store cold per general peptide handling practice.
The fine print: products are sold for laboratory research use only and are not for human or animal consumption. Bodily introduction into humans or animals is strictly prohibited by law. Tirzepatide is not a drug and is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA.